Trials / Terminated
TerminatedNCT01131559
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
Adjunctive Lisdexamfetamine in Bipolar Depression
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Lindner Center of HOPE · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lisdexamfetamine | Oral; 20-70mg/day |
| DRUG | Placebo control | Oral; 20-70mg/day |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2010-05-27
- Last updated
- 2014-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01131559. Inclusion in this directory is not an endorsement.